Mar 11, 2024 08:15AM
Mar 11, 2024 08:15AM
Jan 8, 2024 07:34AM
Jan 8, 2024 07:30AM
Dec 19, 2023 07:30AM
Dec 12, 2023 03:27AM
Dec 11, 2023 08:15PM Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
Nov 2, 2023 09:15AM
Oct 21, 2023 11:31AM
Oct 16, 2023 04:05PM
Oct 9, 2023 04:17PM
Aug 9, 2023 04:01PM
Jun 27, 2023 07:30AM
May 11, 2023 04:30PM Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Apr 18, 2023 01:30PM
Apr 18, 2023 01:30PM
Apr 17, 2023 01:30PM
Apr 17, 2023 01:30PM
Mar 27, 2023 04:05PM
Mar 27, 2023 04:05PM
Mar 14, 2023 06:21PM Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023
Mar 14, 2023 06:21PM
Dec 11, 2022 10:00AM
Dec 11, 2022 10:00AM
Nov 14, 2022 04:01PM
Nov 14, 2022 04:01PM
Nov 3, 2022 09:09AM
Nov 3, 2022 09:09AM Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
Oct 4, 2022 07:30AM
Oct 4, 2022 07:30AM
Oct 4, 2022 07:30AM
Sep 19, 2022 04:06PM
Sep 19, 2022 04:05PM
Sep 19, 2022 04:05PM
Sep 1, 2022 07:30AM Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences
Sep 1, 2022 07:30AM
Aug 10, 2022 04:01PM
Aug 10, 2022 04:01PM
Aug 2, 2022 07:30AM
Aug 2, 2022 07:30AM
Jul 6, 2022 07:30AM
Jul 6, 2022 07:30AM Harpoon Therapeutics Expands Leadership Team
Jul 6, 2022 07:30AM
May 26, 2022 05:01PM
May 26, 2022 05:00PM
May 26, 2022 05:00PM
May 12, 2022 04:05PM
May 12, 2022 04:05PM
May 2, 2022 09:00AM Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer
May 2, 2022 09:00AM

322,966 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All